Trial0

Clinical trial · NCT06090903 · RECRUITING · NA

Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma

Sponsor: Jonsson Comprehensive Cancer Center

We save this real registry record and notify you if its published status changes. Create an account to add profile details that improve future matching.

Summary

This clinical trial uses a type of imaging scan called magnetic resonance imaging (MRI) to study brain tumor biology in patients with glioblastoma that can be removed by surgery (resectable). Malignant gliomas are the second leading cause of cancer mortality in people under the age of 35 in the United States. Glioblastoma is a type of malignant glioma with very poor patient prognosis. There are currently only about 3 drugs approved by the Food and Drug Administration (FDA) for the treatment of glioblastoma, one of them being administration of bevacizumab, which is very expensive. It is the most widely used treatment for glioblastoma with dramatic results. However, previous clinical trials have not demonstrated an overall survival benefit across all patient populations with glioblastoma that has returned after treatment (recurrent). The study aims to identify which patients who will benefit from bevacizumab therapy by observing MRI images and corresponding imaging biomarkers.

Interventions

  • Biospecimen Collection · PROCEDURE

    patients will receive 1-3 image-guided biopsies within tumor tissue already designated for resection or removal.

  • Magnetic Resonance Imaging · PROCEDURE

    Undergo MRI scan

  • Medical Chart Review · OTHER

    Review Medical Chart

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Patients \> 18 years of age
* Patients with newly diagnosed, suspected or recurrent glioblastoma (GBM) patients with enhancing tumors greater than 1.5 mL clinically indicated for surgical resection. Recurrent GBM must have occurred more than 3 months after the end of radiation therapy per Response Assessment in Neuro-Oncology Criteria (RANO) guidelines

Exclusion Criteria:

* Counterindication to magnetic resonance imaging (MRI) (Patient has a pacemaker or metal in the body)
* Patients \< 18 years of age

Sites (1)

  • UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California · RECRUITING

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2025-11-10.